zimmytws

Leqembi, the new Alzheimer’s therapy developed by Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY), could add $2B – $5B costs to Medicare annually, in the event of broader coverage, according to a recently published study.

Early this year, the FDA granted FDA’s

End

To Get The Latest News Update

Sign up to Our Subscription.

We don’t spam! Read our privacy policy for more info.

To Get The Latest News Update

Sign up to Our Subscription.

We don’t spam! Read our privacy policy for more info.

Leave a Reply

Your email address will not be published. Required fields are marked *